论文部分内容阅读
近年来国内外已有用大剂量静脉丙种球蛋白 (IVIG)治疗川崎病 (KS)患者。为进一步确定其疗效 ,用IVIG治疗KS 38例 ,对照组 2 6例用阿斯匹林 (ASP)治疗。IVIG组采用IVIG 4 0 0mg/kg·d连用 4～ 6d ,或 1g/kg·d用 1d ,同时给予阿司匹林 ,直至血小板计数和血沉降至正常。对照组除了未用IVIG外 ,其余治疗相同。资料显示IVIG组的发热消退时间 ,粘膜充血消退时间及手、足肿胀消退时间均明显短于对照组。说明IVIG在控制炎症方面优于ASP。IVIG组冠状动脉扩张(CAD)发生率为 7 9% ,而对照组CAD发生率为 2 3 1% ,两组间差异有显著性 ,进一步证实IVIG能有效地预防冠状动脉损害。
In recent years, large doses of intravenous gamma globulin (IVIG) have been used in patients with Kawasaki disease (KS) at home and abroad. In order to further determine its efficacy, 38 cases were treated with IVIG and 26 cases in control group with aspirin (ASP). IVIG group with IVIG 400mg / kg · d for 4 ~ 6d, or 1g / kg · d with 1d, given aspirin, until the platelet count and erythrocyte sedimentation rate to normal. The control group except IVIG without treatment, the rest of the same treatment. Data show that IVIG group fever subsided time, mucosal congestion and dissipate the time and hand, foot swelling subsided time were significantly shorter than the control group. This shows that IVIG is superior to ASP in controlling inflammation. The incidence of coronary artery dilatation (CAD) in IVIG group was 79%, while that in control group was 23.1%. There was significant difference between the two groups, which further confirmed that IVIG can effectively prevent coronary artery lesion.